Diversified Trust Co Sells 2,148 Shares of Edwards Lifesciences Co. (NYSE:EW)

Diversified Trust Co decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 7.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 26,029 shares of the medical research company’s stock after selling 2,148 shares during the quarter. Diversified Trust Co’s holdings in Edwards Lifesciences were worth $2,404,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Cox Capital Mgt LLC acquired a new position in Edwards Lifesciences during the 2nd quarter valued at about $2,443,000. Burke & Herbert Bank & Trust Co. acquired a new position in Edwards Lifesciences during the 2nd quarter valued at about $1,505,000. M&G Plc lifted its position in Edwards Lifesciences by 4.9% during the 2nd quarter. M&G Plc now owns 9,315 shares of the medical research company’s stock valued at $857,000 after purchasing an additional 431 shares during the period. Wedmont Private Capital lifted its position in Edwards Lifesciences by 6.3% during the 2nd quarter. Wedmont Private Capital now owns 8,704 shares of the medical research company’s stock valued at $792,000 after purchasing an additional 515 shares during the period. Finally, First Community Trust NA acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $29,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on EW shares. Canaccord Genuity Group cut their price target on shares of Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. Robert W. Baird downgraded shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $102.00 to $70.00 in a report on Thursday, July 25th. TD Cowen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating on the stock in a report on Thursday, July 25th. Finally, Stifel Nicolaus decreased their price target on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research note on Thursday, July 25th. Fourteen equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $82.10.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $0.55 during trading on Wednesday, reaching $65.80. The company’s stock had a trading volume of 413,532 shares, compared to its average volume of 4,014,896. The business’s 50-day moving average price is $81.95 and its 200-day moving average price is $86.06. The firm has a market cap of $39.65 billion, a PE ratio of 28.60, a P/E/G ratio of 2.57 and a beta of 1.11. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the prior year, the business posted $0.66 earnings per share. Edwards Lifesciences’s revenue was up 6.7% compared to the same quarter last year. Equities analysts forecast that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Bernard J. Zovighian sold 8,617 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $87.68, for a total value of $755,538.56. Following the completion of the transaction, the chief executive officer now owns 68,218 shares of the company’s stock, valued at $5,981,354.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Scott B. Ullem sold 5,625 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $90.45, for a total value of $508,781.25. Following the completion of the transaction, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,764,242.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 8,617 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $87.68, for a total transaction of $755,538.56. Following the sale, the chief executive officer now directly owns 68,218 shares of the company’s stock, valued at approximately $5,981,354.24. The disclosure for this sale can be found here. Insiders sold 24,242 shares of company stock valued at $2,168,470 over the last quarter. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.